Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + benmelstobart + cisplatin + gemcitabine
- Development stage
- Phase 3
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is a four-drug regimen being investigated for the treatment of advanced or metastatic urothelial carcinoma (bladder cancer). It consists of **anlotinib**, a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits angiogenesis by targeting VEGFR, FGFR, and PDGFR; **benmelstobart** (TQB2450), a humanized monoclonal antibody that blocks the Programmed cell death 1 ligand 1 (PD-L1) to restore anti-tumor immune responses; and the standard-of-care chemotherapy doublet **cisplatin** and **gemcitabine**. The rationale for this combination is to leverage the anti-angiogenic and immunomodulatory effects of anlotinib and the cytotoxic debulking of chemotherapy to enhance the efficacy of PD-L1 inhibition. The regimen is primarily developed by Chia Tai Tianqing (Sino Biopharmaceutical) and is being evaluated in clinical trials led by institutions such as the Sun Yat-sen University Cancer Center.
- Other names
- TQB2450 + anlotinib + gemcitabine + cisplatinTQB2450 + anlotinib + GC
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + benmelstobart + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + benmelstobart + cisplatin + gemcitabine.